Experimental and bioinformatics study for production of l-asparaginase from Bacillus licheniformis: a promising enzyme for medical application

AMB Express

Table 1 Antigenic regions, their positions, and sequences of E. coli, Erwinia chrysanthemi, and Bacillus licheniformis l-asparaginases

E. coli l-asparaginase (348 aa) Accession # D6JF83^a				Erwinia chrysanthemi l-asparaginase (348 aa) Accession # P06608^b				Bacillus licheniformis l-asparaginase (322 aa) Accession # P30363^c
Antigenic region	Start	End	Sequence	Anti-genic region	Start	End	Sequence	Anti-genic region	Start	End	Sequence
1	323	333	KARVLLQLALT	1	6	20	KSLFVLVLFFVFTS	1	195	216	KRDVHQLQRPLPAVDIVKCYLD
2	224	243	PFDVSKLNELPKVGIVYNYA	2	121	142	ESAYFLHLTVKSDKPVVFVAAM	2	304	314	KLAVLLASYKE
3	245	257	ASDLPAKALVDG	3	88	101	GDVVLKLSQRVL	3	256	265	NQGVYIVITT
4	118	135	AYFLDLTVKCDKPVVMVG	4	290	297	KGVVVIRS	4	128	140	NIRHAVYTACSPD
5	6	16	KTALAALVMGF	5	156	165	LLEAVRVAGD	5	184	193	NDKVYVYQKP
6	165	174	NRGVLVVMND	6	311	333	LPGLVSDSLNPAHARILLMLALT	6	144	152	AGTVVVFNE
7	49	70	AGKVGVENLVNAVPQLKDIANV	7	22	34	ADKLPNIVILATG	7	35	58	AEMCSLPEDVQIDVYPAFQLPSMH
8	151	159	LYNAVVTAA	8	172	179	GVMVVLND	8	106	114	ERPVVVTGS
9	286	298	GTAVVRSSRVPTG	9	107	114	VDGVVITH	9	157	168	ARYVKKVHASNL
10	72	79	EQVVNIG	10	251	270	PEYLYDAAIQHGVKGIVYAG	10	231	237	EGIVLEG
11	190	204	VATFKSVNYGPLGYI	11	226	248	TRSVFDVRGLTSLPKVDILYGYQ	11	170	181	GFDVFGFGYLGI
12	259	265	DGIVSAG	12	205	214	YLGVIIGNRI	12	95	102	TAYFLDLT
13	88	94	WLTLAKK	13	52	73	AGALGVDTLINAVPEVKKLANV	13	60	68	TFEHLLELK
14	18	32	GAALALPNITILAG	14	337	345	DPKVIQEYF	14	81	87	DGAVVTH
15	272	282	YKTVFDTLATA	15	274	281	GSVSVRGI	15	4	9	KVALIT
16	311	317	YGFVASG	16	303	309	GIVPPDE	16	278	294	YAGSSYDLAKKGVILGK
17	339	345	QQIQQIF					17	24	29	LAAGAI
18	104	109	GFVITH

^aE. coli FDA approved l-asparaginase (marketed under the brand name Elspar)
^bErwinia chrysanthemi (Dickeya chrysanthemi or Pectobacterium chrysanthemi) l-asparaginase (marketed under the brand name Erwinaze)
^cBacillus licheniformis l-asparaginase